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RAPID COMMUNICATION
All-Oral 12-Week Treatment With Daclatasvir Plus
Sofosbuvir in Patients With Hepatitis C Virus Genotype
3 Infection: ALLY-3 Phase III Study
David R. Nelson,1 James N. Cooper,2 Jacob P. Lalezari,3 Eric Lawitz,4 Paul J. Pockros,5 Norman Gitlin,6
Bradley F. Freilich,7 Ziad H. Younes,8 William Harlan,9 Reem Ghalib,10 Godson Oguchi,11
Paul J. Thuluvath,12 Grisell Ortiz-Lasanta,13 Mordechai Rabinovitz,14 David Bernstein,15 Michael Bennett,16
Trevor Hawkins,17 Natarajan Ravendhran,18 Aasim M. Sheikh,19 Peter Varunok,20 Kris V. Kowdley,21
Delphine Hennicken,22 Fiona McPhee,23 Khurram Rana,23 and Eric A. Hughes,24
on behalf of the ALLY-3 Study Team
Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are
limited, with the currently approved all-oral regimens requiring 24-week treatment and
the addition of ribavirin (RBV). This phase III study (ALLY-3; ClinicalTrials.gov:
NCT02032901) evaluated the 12-week regimen of daclatasvir (DCV; pangenotypic nonstructural protein [NS]5A inhibitor) plus sofosbuvir (SOF; pangenotypic NS5B inhibitor) in patients infected with genotype 3. Patients were either treatment na€ıve (n 5 101)
or treatment experienced (n 5 51) and received DCV 60 mg plus SOF 400 mg oncedaily for 12 weeks. Coprimary endpoints were the proportions of treatment-na€ıve and
treatment-experienced patients achieving a sustained virological response (SVR) at posttreatment week 12 (SVR12). SVR12 rates were 90% (91 of 101) and 86% (44 of 51) in
treatment-na€ıve and treatment-experienced patients, respectively; no virological breakthrough was observed, and 99% of patients had a virological response (VR) at the end
of treatment. SVR12 rates were higher in patients without cirrhosis (96%; 105 of 109)
than in those with cirrhosis (63%; 20 of 32). Five of seven patients who previously
failed treatment with an SOF-containing regimen and 2 of 2 who previously failed treatment with an alisporivir-containing regimen achieved SVR12. Baseline characteristics,
including gender, age, HCV-RNA levels, and interleukin-28B genotype, did not impact
virological outcome. DCV plus SOF was well tolerated; there were no adverse events
(AEs) leading to discontinuation and only 1 serious AE on-treatment, which was unrelated to study medications. The few treatment-emergent grade 3/4 laboratory abnormalities that were observed were transient. Conclusion: A 12-week regimen of DCV plus
SOF achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis
and was well tolerated. Additional evaluation to optimize efficacy in genotype
3–infected patients with cirrhosis is underway. (HEPATOLOGY 2015;61:1127-1135)

C

hronic infection with hepatitis C virus (HCV)
genotype 3 is common throughout the world
and remains a significant disease burden for
many patients.1,2 Infection with HCV genotype 3 has
been associated with an increased risk of progression

to cirrhosis, as well as development of steatosis or
hepatocellular carcinoma (HCC), compared with other
HCV genotypes.3-5 In an observational cohort study,
analysis of real-world data from the Veterans Affairs
HCV clinical registry found that the risks of cirrhosis,

Abbreviations: AE, adverse event; ALT, alanine aminotransferase; ALV, alisporivir; APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; CI, confidence interval; DAAs, direct-acting antivirals; DCV, daclatasvir; HCC, hepatocellular carcinoma; Hgb, haemoglobin; HCV, hepatitis C
virus; HIV, human immunodeficiency virus; IFN, interferon; IL28B, interleukin-28B; INR, international normalized ratio; kPA, kilopascals; LDV, ledipasvir;
LLOQ, lower limit of quantitation; NS, nonstructural; Peg-IFN, pegylated IFN; PLT, platelet; RAV, resistance-associated variant; RBV, ribavirin; SAEs, serious
AEs; SOF, sofosbuvir; SVR, sustained virological response; SVR12, SVR at post-treatment week 12; VBT, virological breakthrough; VF, virological failure; VR, virological response.
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HCC, liver-related hospitalization, and death were significantly higher in genotype 3–infected patients, compared with genotype 1–infected patients,6 underscoring
the medical need for safe, effective treatment options
for patients with genotype 3 infection. Recent advances have led to the approval of interferon (IFN)-free
and/or ribavirin (RBV)-free therapies for chronic infection with HCV genotypes 1, 2, 3, and 4. However,
for both treatment-na€ıve and treatment-experienced
patients with genotype 3 infection, IFN- and RBV-free
therapy options are currently limited.
Therapies approved in the United States and
Europe for treatment of genotype 3 infection include a
24-week, all-oral regimen of sofosbuvir (SOF; a pangenotypic nonstructural protein [NS]5B inhibitor) in
combination with RBV7,8 and a 24-week regimen of
pegylated IFN (Peg-IFN) plus RBV.9,10 In addition, a
12-week, IFN-based regimen of SOF plus Peg-IFN
and RBV8 is approved in Europe for treating genotype
3 infection, as are all-oral, 24-week regimens of daclatasvir (DCV; a potent, pangenotypic NS5A inhibitor)
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plus SOF with RBV11 and ledipasvir (LDV; an NS5A
inhibitor) plus SOF with RBV12 for patients with compensated cirrhosis and/or previous treatment experience.
The all-oral combination of SOF plus RBV requires 24
weeks of treatment because 12- and 16-week treatment
durations were associated with lower response rates
(30%-61% and 62%, respectively) in genotype 3–
infected patients.7,13,14 With 24-week treatment, lower
response rates were observed in genotype 3–infected
patients who were treatment experienced (77%), particularly those with cirrhosis (60%), compared with those
who were treatment na€ıve (93%).7,15 In addition, there
was an increased incidence of anemia, which is consistent with the hemolytic anemia known to occur with
RBV treatment.15,16 Thus, patients with genotype 3
infection have a need for improved treatment options,
preferably with therapies of shorter duration and without the addition of Peg-IFN or RBV.
DCV was evaluated in combination with SOF in a
phase II study.17 Treatment for 24 weeks with DCV
plus SOF, with or without the addition of RBV, resulted
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in an 89% rate of sustained virological response (SVR)
at post-treatment week 12 (SVR12) among 18
treatment-na€ıve patients with genotype 3 infection.11,17
Of 5 genotype 3–infected patients who had F3 fibrosis
(based on FibroTest scores), all 5 achieved SVR12.11 In
this phase III study, the efficacy and safety of 12-week,
RBV-free treatment with DCV plus SOF were evaluated
in treatment-na€ıve and treatment-experienced patients
chronically infected with HCV genotype 3.

Patients and Methods
Study Design and Patients. This was an openlabel, two-cohort phase III study (ClinicalTrials.gov:
NCT02032901) of a 12-week regimen of DCV plus
SOF in genotype 3 infection. Eligible patients were
males and females 18 years of age with chronic genotype 3 infection who were either treatment na€ıve or
treatment-experienced and had HCV-RNA levels
10,000 IU/mL at screening. Treatment-na€ıve patients
had no previous exposure to any IFN formulation,
RBV, or any HCV direct-acting antiviral (DAA) agent,
whereas treatment-experienced patients received previous therapy with IFN-a (with or without RBV), SOF
plus RBV, or other anti-HCV agents, such as inhibitors
of cyclophilin or microRNA. Patients who received previous therapy with NS5A inhibitors and those who previously discontinued treatment with SOF plus RBV
prematurely because of intolerance (other than exacerbation of anemia) were excluded. All permitted previous
anti-HCV therapies must have been completed or discontinued at least 12 weeks before screening.
Patients with compensated cirrhosis were eligible (up
to 50% in each cohort), with cirrhosis determined by
liver biopsy (Metavir F4) at any time before screening,
FibroScan (>14.6 kilopascals [kPa]) within 1 year of
baseline (day 1), or a FibroTest score 0.75 coupled
with an aspartate aminotransferase (AST) to platelet ratio
index (APRI) >2. Per the study protocol, FibroTest
assessments (scores determined by BioPredictive) were
performed during screening; a FibroTest score 0.74
corresponded to a fibrosis stage of F0-F3, and a score
>0.74 corresponded to a fibrosis stage of F4. Key patient
exclusion criteria included chronic liver disease other
than that related to HCV infection, infection with HCV
genotypes other than genotype 3 or with mixed genotypes, coinfection with human immunodeficiency virus
(HIV) or hepatitis B virus, documented or suspected
HCC, or evidence of hepatic decompensation.
All patients received open-label treatment with
DCV 60 mg plus SOF 400 mg once-daily for 12
weeks, with a subsequent 24-week follow-up. The
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study was conducted in accord with the ethical principles that originated in the Declaration of Helsinki,
and the study protocol was approved by the institutional review board or independent ethics committee
at each study site. All patients provided written
informed consent before participation in the study.
Study Assessments. Adherence to study treatment
was assessed at each study visit based on tablet counts
and dosing information recorded in patient diaries.
HCV-RNA levels were determined at baseline; ontreatment weeks 1, 2, 4, 6, 8, and 12; and posttreatment weeks 4, 12, and 24 using the COBAS
TaqMan HCV test (version 2.0; Roche Molecular
Systems, Pleasanton, CA), with a lower limit of quantitation (LLOQ) of 25 IU/mL. HCV genotype or subtype was determined using the RealTime HCV
genotype II assay (Abbott Molecular, Abbott Park, IL)
and confirmed by viral sequence analysis. Interleukin28B (IL28B) genotype (rs12979860 single-nucleotide
polymorphism) was determined by polymerase chain
reaction amplification and sequencing. Resistance testing was performed by population-based sequencing of
plasma samples from all patients at baseline and from
patients with virological failure (VF) who had HCVRNA levels of 1,000 IU/mL. VFs included virological breakthrough (VBT), defined as a confirmed, ontreatment HCV-RNA increase of 1 log10 IU/mL
from nadir or a confirmed HCV-RNA measurement
of LLOQ following a previous measurement of
<LLOQ; relapse, defined as a confirmed HCV-RNA
measurement of LLOQ post-treatment following an
undetectable HCV-RNA measurement at the end of
treatment; and HCV-RNA measurement of LLOQ
at any time point not meeting the definition of VBT
or relapse. Safety and tolerability were assessed based
on adverse event (AE) reporting, clinical laboratory
tests, vital signs, and physical examinations.
Statistical Analyses. The coprimary endpoints
were the proportions of treatment-na€ıve and treatmentexperienced patients achieving SVR12 (defined as
HCV-RNA levels <LLOQ, either detectable or undetectable). Target sample sizes of 100 treatment-na€ıve
and 50 treatment-experienced patients would provide
95% confidence intervals (CI) for the observed SVR12
rates of within 9.7% and 14.2%, respectively, when the
observed SVR12 rates were 75%. In the treatmentna€ıve cohort, a target sample size of 100 patients would
provide a 95% CI lower bound of >76% with an
observed SVR12 rate of 85%. In the treatmentexperienced cohort, a target sample size of 50 patients
would provide a 95% CI lower bound of >73% with
an observed SVR12 rate of 86%.
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Secondary efficacy endpoints included the proportion of patients achieving HCV-RNA levels <LLOQ,
detectable or undetectable, at on-treatment weeks 1, 2,
4, 6, and 8, the end of treatment, and post-treatment
weeks 4 and 24; the proportion achieving HCV-RNA
levels <LLOQ, undetectable, at on-treatment weeks 1,
2, 4, 6, and 8 and the end of treatment; and SVR12
rates by baseline cirrhosis status and IL28B genotype.
Efficacy analyses included all patients who received 1
dose of study medications, and response rates and
two-sided 95% exact binomial CI were estimated by
cohort for efficacy endpoints.

Results
Patients. A total of 152 patients received 1 dose
of study medications; of these, 101 (66%) were treatment na€ıve and 51 (34%) were treatment experienced.
Treatment-experienced patients included those who
had previously failed treatment with IFN-based therapies or other anti-HCV therapies, including SOF- and
alisporivir (ALV)-containing regimens (Table 1). One
hundred (99%) treatment-na€ıve patients and all 51
(100%) treatment-experienced patients completed 12
weeks of treatment; 1 treatment-na€ıve patient discontinued treatment after week 8 because of pregnancy,
but achieved SVR12.
Overall, patients were 90% white and 59% male,
with a median age of 55 years; the majority of patients
had baseline HCV-RNA levels of 800,000 IU/mL
(71%) and a non-CC IL28B genotype (61%; Table 1).
All patients were chronically infected with HCV genotype 3. Cirrhosis, as determined by liver biopsy,
FibroScan, or FibroTest/APRI per protocol, was present in 21% of patients overall (treatment na€ıve, 19%;
treatment experienced, 25%). Fibrosis stage was also
determined using FibroTest scores, based on which,
119 (78%) patients had a fibrosis stage of F0-F3 and
30 (20%) had a fibrosis stage of F4; FibroTest scores
were not reported for 3 patients (all 3 achieved
SVR12). Baseline albumin levels were similar in
patients with cirrhosis (median, 41 g/L; range, 33-47)
and without cirrhosis (median, 44 g/L; range, 36-53);
baseline platelet (PLT) counts were lower in patients
with cirrhosis (median, 124.5 3 109/L; range, 62-382)
than in those without cirrhosis (median, 200 3 109/L;
range, 89-334).
Virological Response. DCV plus SOF for 12
weeks achieved SVR12 rates of 90% in treatmentna€ıve patients and 86% in treatment-experienced
patients with genotype 3 infection, with an overall
SVR12 rate of 89% (Table 2). Rapid and sustained
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Table 1. Demographic and Baseline Disease Characteristics

Parameter

Age, median (range) years
Male, n (%)
Race, n (%)
White
Black
Asian
Other
Body mass index, mean kg/m2 (SD)
HCV-RNA level, IU/mL, n (%)‡
<800,000
800,000
IL28B genotype, n (%)
CC
CT
TT
Cirrhosis, n (%)§,k
Fibrosis stage by FibroTest, n (%)¶
F0-F3
F4
Past treatment category, n (%)
Relapse
Null response
Partial response
Other treatment failures#

Treatment
Na€ıve
(N 5 101)

53 (24-67)
58 (57)
92 (91)
4 (4)
5 (5)
0
26.55 (4.25)

Treatment
Experienced*
(N 5 51)

58 (40-73)
32 (63)
45
2
2
2
28.22

(88)
(4)
(4)
(4)†
(3.77)

31 (31)
70 (69)

13 (25)
38 (75)

40
47
14
19

20
21
10
13

(40)
(47)
(14)
(19)

76 (75)
22 (22)
NA
NA
NA
NA

(39)
(41)
(20)
(25)

43 (84)
8 (16)
31
7
2
11

(61)
(14)
(4)
(22)

*Includes patients who previously failed treatment with IFN-based therapies
or other anti-HCV therapies, including SOF (n 5 7) and ALV (n 5 2).
†
American Indian/Alaska native.
‡
All patients were infected with HCV genotype 3a.
§
Cirrhosis was determined by liver biopsy (Metavir F4; n 5 14), FibroScan
(>14.6 kPa; n 5 11), or FibroTest score 0.75 and APRI >2 (n 5 7); for 11
patients, cirrhosis status was missing or inconclusive (FibroTest score >0.48 to
<0.75 or APRI >1 to 2).
k
Of the 32 patients with cirrhosis, 11 (34%) had baseline PLT counts of
100 3 109 cells/L.
¶
Per the study protocol, FibroTest assessments were performed during screening (FibroTest scores not available for 3 treatment-na€ıve patients); F0-F3
defined as FibroTest score of 0.74, and F4 defined as FibroTest score of
>0.74.
#
Includes intolerance (n 5 6), breakthrough (n 5 2), HCV RNA never undetectable on treatment (n 5 2), and indeterminate (n 5 1).
Abbreviations: SD, standard deviation; NA, not applicable.

reductions from baseline in HCV-RNA levels were
observed, with mean decreases of 4.3-4.5 log10 IU/mL
at on-treatment week 1 and 4.7-4.9 log10 IU/mL at
on-treatment week 2. The proportion of patients
achieving HCV-RNA levels <LLOQ, detectable or
undetectable, at early on-treatment time points in the
treatment-na€ıve and treatment-experienced cohorts,
respectively, was 40% and 24% for week 1, 77% and
69% for week 2, and 94% and 98% for week 4.
HCV-RNA levels were undetectable at end of treatment in 99% of patients.
The relationship between virological response (VR)
at early on-treatment time points and achievement of
SVR12 was assessed. SVR12 was achieved by 94% of
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Table 2. Virological Response
Parameter

SVR12, n (%) [95% CI]*
On-treatment response, n (%) [95% CI]
Week 1
HCV RNA <LLOQ, detectable or undetectable
Week 2
HCV RNA <LLOQ, detectable or undetectable
Week 4
HCV RNA <LLOQ, detectable or undetectable
HCV RNA undetectable
End of treatment
HCV RNA <LLOQ, detectable or undetectable
HCV RNA undetectable
Patients without SVR12
VBT, n (%)‡
Other on-treatment failure, n (%)
Post-treatment relapse, n/N (%)k¶

Treatment Na€ıve (N 5 101)

Treatment Experienced (N 5 51)

91 (90) [83, 95]

44 (86) [74, 94]

40 (40) [30, 50]

12 (24) [13, 37]

78 (77) [68, 85]

35 (69) [54, 81]

95 (94) [88, 98]
64 (63) [53, 73]

50 (98) [90, 100]
37 (73) [58, 84]

100 (99) [95, 100]†
100 (99) [95, 100]†

51 (100) [93, 100]
51 (100) [93, 100]

0
1 (1)§
9/100 (9)

0
0
7/51 (14)

*HCV RNA <LLOQ (25 IU/mL), detectable or undetectable.
One patient who discontinued after week 8 (because of pregnancy) and achieved SVR12 was included in the number of patients achieving a VR at end of treatment (n 5 100), but not at week 12 (n 5 99).
‡
Defined as a confirmed HCV-RNA increase from nadir of 1 log10 IU/mL on-treatment or a confirmed HCV-RNA measurement of LLOQ after a previous measurement of <LLOQ.
§
One patient with cirrhosis who had a quantifiable HCV-RNA level (53 IU/mL) at end of treatment (did not meet the protocol definition of VBT, which required
on-treatment confirmation of the HCV-RNA measurement).
k
Defined as a confirmed HCV-RNA measurement of LLOQ post-treatment after an undetectable HCV-RNA measurement at end of treatment; percentages are
based on the numbers of patients with undetectable HCV RNA at end of treatment.
¶
Of the 16 patients with post-treatment relapse, 11 had cirrhosis at baseline; 1 relapse, in a treatment-na€ıve patient without cirrhosis, occurred between posttreatment week 4 and post-treatment week 12.
†

patients with HCV-RNA levels <LLOQ, detectable or
undetectable, and 86% of patients with HCV-RNA
levels LLOQ, at week 1; 92% and 79% of patients
with HCV-RNA levels <LLOQ, detectable or undetectable, or LLOQ, respectively, at week 2 achieved
SVR12. Among patients with HCV-RNA levels
<LLOQ, detectable or undetectable, at week 4, 90%
achieved SVR12, compared with 71% of patients with
HCV-RNA levels LLOQ. When VR at week 4 was
assessed based on undetectable HCV-RNA levels, the
proportion of patients with a week 4 response who
achieved SVR12 was 91%.

Fig. 1. VR by baseline characteristics. aHCV RNA <LLOQ
(25 IU/mL), detectable or
undetectable; error bars reflect
95% CI.

Analysis of SVR12 in patient subgroups based on baseline characteristics showed no notable differences by gender, age, HCV-RNA levels, or IL28B genotype (Fig. 1).
Among treatment-experienced patients, SVR12 was
achieved by 25 of 31 patients with previous relapse and by
all 7 null responders, 2 partial responders, and 2 patients
who experienced VBT with past treatment. In addition, all
6 patients who were intolerant of past treatment achieved
SVR12, as did 2 of 3 patients with other types of past
treatment failure (HCV-RNA never undetectable on treatment or indeterminate). SVR12 was achieved in 5 of 7
patients who previously failed treatment with an SOF-
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Fig. 2. VR in patients with (A)
cirrhosis or (B) fibrosis stage of F4
(FibroTest). aHCV RNA <LLOQ (25
IU/mL), detectable or undetectable; error bars reflect 95% CI.
b
Among 32 patients with cirrhosis,
11 (34%) had baseline PLT counts
100 3 109 cells/mL. cCirrhosis
status determined in 141 patients
by liver biopsy (Metavir F4),
FibroScan (>14.6 kPa), or
FibroTest score 0.75 and APRI
>2; for 11 patients, cirrhosis status was missing or inconclusive
(FibroTest score >0.48 to <0.75
or APRI >1 to 2). dPer the study
protocol, FibroTest assessments
were performed during screening
(FibroTest scores not available for
3 treatment-na€ıve patients); F0-F3
defined as FibroTest score of
0.74 and F4 defined as FibroTest
score of >0.74.

containing regimen and in both patients who previously
failed treatment with an ALV-containing regimen.
SVR12 rates were higher in patients without cirrhosis (96%) than in patients with cirrhosis (63%;
Fig. 2A), although high response rates at end of treatment were noted both in patients with and without
cirrhosis (97% and 100%, respectively). A similar
trend was observed when SVR12 was analyzed by
fibrosis stage, based on FibroTest scores, of F0-F3
(93%) and F4 (70%; Fig. 2B). Overall, results by cirrhosis status or by fibrosis stage based on FibroTest
scores were generally consistent between the treatmentna€ıve and treatment-experienced cohorts. VR at early
on-treatment time points did not appear to impact
SVR12 rates in patients with cirrhosis, given that the
proportion of patients with cirrhosis who achieved
SVR12 was the same among those who did or did not
have undetectable HCV-RNA levels at on-treatment
week 4 (10 of 16 patients with undetectable HCVRNA levels at week 4 and 10 of 16 patients without
undetectable HCV-RNA levels at week 4 achieved
SVR12).
The relationship between resistance-associated variants (RAVs) at NS5A amino acid positions M28,
A30, L31, and Y93 at baseline and SVR12 was

assessed. No patients had L31 polymorphisms at baseline; 1 patient without cirrhosis had M28V at baseline
and achieved SVR12. NS5A-A30 polymorphisms were
detected in 14 of 147 patients at baseline. Of the 14
patients with A30 polymorphisms, 9 of 9 without cirrhosis and 1 of 5 with cirrhosis achieved SVR12.
Among the 4 patients with cirrhosis with baseline A30
polymorphisms who did not achieve SVR12, 2 also
had Y93H at baseline, 1 had A30T, which has no
effect on DCV potency in vitro, and 1 had A30K,
which was associated with SVR12 in the 5 remaining
patients with this polymorphism.18 NS5A-Y93H was
detected in 13 of 147 patients who had NS5A
sequence at baseline; of these 13 patients, 6 of 9 without cirrhosis and 1 of 4 with cirrhosis achieved
SVR12. No NS5B RAVs were detected at amino acid
positions associated with resistance to SOF (159, 282,
or 321) at baseline.
Virologic Failure. Occurrence of VF was low, with
no VBTs observed (Table 2). One treatment-na€ıve
patient with cirrhosis had a quantifiable HCV-RNA level
of 53 IU/mL at end of treatment; this event did not
meet the protocol definition of VBT, which required
on-treatment confirmation of the HCV-RNA measurement. The patient was a slow responder through week 4
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Table 3. Safety and Tolerability
Parameter, n (%)*

Death
SAEs
AE leading to discontinuation
Grade 3 AEs
Grade 4 AEs
AEs in 5% of patients (all grades)
Headache
Fatigue
Nausea
Diarrhea
Insomnia
Abdominal pain
Arthralgia
Grade 3/4 laboratory abnormalities§
Hgb <9.0 g/dL
Absolute neutrophils <0.75 3 109 cells/L
Absolute lymphocytes <0.5 3 109 cells/L
PLTs <50 3 109 cells/L
INR >23 ULN
ALT >53 ULN
AST >53 ULN
Total bilirubin >2.53 ULN
Lipase >33 ULN

All Patients (N 5 152)

0
1 (1)†
0
3 (2)‡
0
30
29
18
13
9
8
8

(20)
(19)
(12)
(9)
(6)
(5)
(5)

0
0
1 (1)
2 (1)
2 (1)
0
0
0
3 (2)

*On-treatment events for death and AEs; treatment-emergent events for
grade 3/4 laboratory abnormalities.
†
One event of gastrointestinal hemorrhage at week 2, considered not related
to study treatment.
‡
Arthralgia in 1 patient; food poisoning, nausea, and vomiting in 1 patient;
and SAE of gastrointestinal hemorrhage in 1 patient.
§
Primarily transient increases or decreases that were not present for prolonged periods during treatment.
Abbreviation: ULN, upper limit of normal.

and had a low baseline PLT count (83 3 109 cells/L),
reflecting advanced cirrhosis. Sixteen patients (9 treatment na€ıve and 7 treatment experienced) had posttreatment relapse, of whom 11 (7 treatment na€ıve and 4
treatment experienced) had cirrhosis at baseline. All of
the relapses occurred by post-treatment week 4 except
for 1, which occurred between post-treatment week 4
and post-treatment week 12 in a treatment-na€ıve patient
without cirrhosis. Factors that may have contributed to
treatment failure in this patient included a very high
baseline HCV-RNA level (27.5 3 106 IU/mL), presence
of the NS5A-Y93H RAV at baseline, and incomplete
treatment adherence (93% adherent), although no relapses occurred among the other 4 patients who were not
completely adherent to treatment (3 with 90%-95%
adherence and 1, who discontinued after week 8 because
of pregnancy, with 66% adherence). The NS5A-Y93H
RAV emerged in 9 of 16 patients with relapse; of the
remaining 7 patients with relapse, 6 had NS5A-Y93H at
baseline and 1 had emergent NS5A-L31I. NS5B RAVs
at amino acid positions associated with resistance to
SOF (159, 282, or 321) were not detected at relapse.

1133

Safety and Tolerability. DCV plus SOF was well
tolerated, with no AEs leading to discontinuation of
treatment (Table 3). There were no deaths and only 1
serious AE (SAE) was reported on-treatment: an event
of gastrointestinal hemorrhage that was considered not
related to study medications. The most common AEs
(in >10% of patients) were headache, fatigue, and
nausea, and the incidence of grade 3 AEs was low
(2%), with no grade 4 AEs reported.
Few treatment-emergent grade 3/4 laboratory abnormalities were observed with DCV plus SOF, with such
events reported only for absolute lymphocytes, PLTs,
international normalized ratio (INR), and lipase.
Incidences of these grade 3/4 laboratory abnormalities
were low (2% each), and none led to clinically significant bleeding or pancreatitis or to treatment discontinuation. Moreover, these abnormalities were
primarily transient increases or decreases that were not
present for prolonged periods during treatment. No
treatment-emergent grade 3/4 abnormalities were
observed in hemoglobin (Hgb) or liver-related parameters, including alanine aminotransferase (ALT) and
AST and total bilirubin.

Discussion
In patients chronically infected with HCV genotype
3, the all-oral, 12-week regimen of DCV plus SOF
achieved SVR12 rates of 90% in treatment-na€ıve
patients and 86% in treatment-experienced patients;
SVR12 was achieved in 96% of patients without cirrhosis and in 63% of patients with cirrhosis. No VBTs
were observed, and all but 1 patient achieved a VR at
end of treatment. The combination of DCV plus SOF
was well tolerated, with a low incidence of SAEs, no
deaths or AEs leading to discontinuation, and few
treatment-emergent grade 3/4 laboratory abnormalities.
These results are generally consistent with those from a
phase II study demonstrating the efficacy and tolerability of DCV plus SOF, with or without RBV, in
patients with genotype 3 infection.17 Overall, findings
from the present study show that in genotype 3–
infected patients without cirrhosis, a 12-week treatment with DCV plus SOF is efficacious, compared
with the current 24-week, all-oral regimens containing
RBV.
SVR12 rates were comparable across subgroups
based on gender, age, baseline HCV-RNA levels, and
IL28B genotype. Notably, this study included patients
who previously failed treatment with SOF- or ALVcontaining regimens, of whom 71% and 100%,
respectively, achieved SVR12. A limitation of the study
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is that the impact of race on SVR12 rates could not
be fully assessed owing to the high proportion of white
patents enrolled (90% overall); however, all 6 of the
black patients enrolled in the study achieved SVR12.
SVR12 rates with DCV plus SOF were higher in
patients without cirrhosis than in those with cirrhosis,
and in patients with a fibrosis stage (based on
FibroTest scores) of F0-F3 than in those with F4.
However, the 63% SVR12 rate in patients with cirrhosis is comparable to that achieved with 16 (61%) or
24 weeks (67%) of SOF plus RBV, with the advantages of an IFN-free and shorter-duration regimen.7
On-treatment and end-of-treatment response rates
were similar in patients with or without cirrhosis, with
relapse accounting for all but one of the treatment failures: among the 16 patients with relapse, 11 had cirrhosis. Relapse was more frequent in the 4 patients
with cirrhosis who had Y93H RAVs at baseline,
although these RAVs did not measurably affect ontreatment response. Other possible reasons for the
higher relapse rate in genotype 3–infected patients
with cirrhosis remain uncertain. Given that high
relapse rates have also been observed with other alloral regimens after treatment of genotype 3 infection,14,18 this HCV genotype may be more difficult
than others to eradicate with DAAs, particularly in
patients with cirrhosis. Multiple factors may contribute
to this effect and require further study.
The robust on-treatment VR with DCV plus SOF,
with nearly all VFs the result of post-treatment relapse,
suggests that optimizing treatment outcomes in
patients with cirrhosis could include the addition of
RBV or a longer treatment duration. A randomized
study
has
been
initiated
(clinicaltrials.gov:
NCT02319031)19 in which patients with genotype 3
infection and compensated advanced cirrhosis are
receiving DCV in combination with SOF and RBV
for 12 or 16 weeks, with the objective of determining
whether adding RBV and extending treatment will
improve the durability of response post-treatment.
This strategy has been successful with other all-oral
regimens. A recent report regarding a phase II study of
SOF plus GS-5816, with or without RBV, suggests
that the addition of RBV improves response rates in
genotype 3–infected patients with cirrhosis. In
treatment-experienced patients with cirrhosis treated
for 12 weeks, SVR12 rates were higher with SOF plus
GS-5816 with the addition of RBV (85%-96%) than
with sofosbuvir plus GS-5816 alone (58%-88%).20
The combination of LDV plus SOF with RBV for 12
weeks has been reported to provide SVR12 rates of
89% in genotype 3–infected, treatment-experienced
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patients without cirrhosis and a lower rate of 77% in
those with cirrhosis.21 Because DCV has shown greater
potency in vitro against genotype 3, compared with
LDV,11,22-24 the combination of DCV plus SOF, with
the addition of RBV, may be expected to provide
improved response rates relative to the current results in
patients with cirrhosis. DCV plus SOF, with or without
RBV, is also being evaluated in additional patient populations with high unmet medical needs in other studies of the ALLY phase 3 program. These include
patients who have cirrhosis or who are post–liver transplant (ALLY-1; ClinicalTrials.gov: NCT02032875) and
patients who are coinfected with HIV (ALLY-2;
ClinicalTrials.gov: NCT02032888). DCV has been
approved in combination with other anti-HCV agents
in Europe and Japan.
DCV plus SOF was associated with a favorable
safety profile. Incidences of SAEs and grade 3/4 AEs
were low, and no deaths or AEs leading to discontinuation were reported. Few grade 3/4 laboratory abnormalities were reported, and the events that were
observed were primarily transient changes and did not
lead to treatment discontinuation. No grade 3/4
abnormalities in Hgb emerged during treatment,
whereas previous studies have reported reductions in
Hgb levels with the combination of SOF plus
RBV.14,15 Overall, no notable safety concerns were
observed with the combination of DCV plus SOF.
In summary, a 12-week regimen of DCV plus SOF
achieved SVR12 in 96% of treatment-na€ıve and
treatment-experienced patients with genotype 3 infection without cirrhosis and was well tolerated. This regimen, without the addition of RBV and with a shorter
treatment duration relative to currently approved alloral regimens, demonstrated high SVR12 rates across
patient subgroups, except in patients with cirrhosis
and regardless of past treatment response. These findings support the 12-week regimen of DCV plus SOF
as an efficacious, well-tolerated treatment option.
Additional evaluation to optimize efficacy in genotype
3–infected patients with cirrhosis is underway.19
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